In conclusion, this study provides strong evidence that CK may exert therapeutic effects by inhibiting the HIF-1α-mediated glycolysis pathway by downregulating the expression of Bclaf1 in liver cancer cells, and thereby inhibiting cell proliferation and cancer progression in the hypoxic microenvironment observed in liver cancer. Here, BCLAF1 is linked to liver cancer.